Literature DB >> 23740131

Correction of hyperphosphatemia suppresses cardiac remodeling in uremic rats.

Ai Yamazaki-Nakazawa1, Masahide Mizobuchi, Hiroaki Ogata, Chiaki Kumata, Fumiko Kondo, Naoko Ono, Fumihiko Koiwa, Susumu Uda, Eriko Kinugasa, Tadao Akizawa.   

Abstract

BACKGROUND: Hyperphosphatemia is associated with cardiovascular disease in patients with chronic kidney disease. To examine the effects of correction of hyperphosphatemia, we investigated the association between phosphate metabolism and cardiac remodeling in uremic rats.
METHODS: Four groups were studied for 8 weeks: (1) control (sham), (2) 5/6 nephrectomized (Nx) rats fed a normal phosphate regular diet (Nx + NP), (3) Nx rats fed a high phosphate (1.2 %) diet (Nx + HP), and (4) Nx rats fed a high phosphate diet containing 2 % lanthanum carbonate (Nx + HP + La). The relationship between phosphate metabolism and cardiac remodeling was analyzed.
RESULTS: Nx + HP rats showed a significant increase in serum phosphate and PTH compared with Nx + NP rats, while Nx + HP + La rats showed slight decreases in these levels. Both Nx + HP and Nx + HP + La rats showed a significant increase in fibroblast growth factor-23 (FGF23) compared with Nx + NP rats. Urinary phosphate excretion showed a similar trend to that of FGF23. Nx + HP rats showed a significant increase in LV weight and matrix deposition compared with Nx + NP rats, and this increase was also significantly suppressed in Nx + HP + La rats. Serum phosphate levels and PTH were significantly correlated with LV weight and matrix deposition, but FGF23 levels did not show the correlation. FGF23 had a high correlation with urinary phosphate excretion.
CONCLUSIONS: These results suggest that correction of hyperphosphatemia by lanthanum carbonate could suppress cardiac remodeling independently of changes in FGF23.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23740131     DOI: 10.1007/s10157-013-0816-6

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  33 in total

1.  Changes in heart rate variability in chronic uremic patients during ultrafiltration and hemodialysis.

Authors:  F Galetta; A Cupisti; F Franzoni; E Morelli; R Caprioli; P Rindi; G Barsotti
Journal:  Blood Purif       Date:  2001       Impact factor: 2.614

2.  Plasma aminothiol oxidation in chronic hemodialysis patients.

Authors:  Jonathan Himmelfarb; Elizabeth McMenamin; Ellen McMonagle
Journal:  Kidney Int       Date:  2002-02       Impact factor: 10.612

3.  Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study.

Authors:  Juan Carlos Ayus; M Reza Mizani; Steven G Achinger; Ravi Thadhani; Alan S Go; Shuko Lee
Journal:  J Am Soc Nephrol       Date:  2005-07-20       Impact factor: 10.121

4.  Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study.

Authors:  Ronald M A Henry; Piet J Kostense; Griët Bos; Jacqueline M Dekker; Giel Nijpels; Robert J Heine; Lex M Bouter; Coen D A Stehouwer
Journal:  Kidney Int       Date:  2002-10       Impact factor: 10.612

5.  Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial.

Authors:  Bruce F Culleton; Michael Walsh; Scott W Klarenbach; Garth Mortis; Narine Scott-Douglas; Robert R Quinn; Marcello Tonelli; Sarah Donnelly; Matthias G Friedrich; Andreas Kumar; Houman Mahallati; Brenda R Hemmelgarn; Braden J Manns
Journal:  JAMA       Date:  2007-09-19       Impact factor: 56.272

6.  Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients.

Authors:  Heng Jung Hsu; Mai-Szu Wu
Journal:  Am J Med Sci       Date:  2009-02       Impact factor: 2.378

7.  Phosphorus binders and survival on hemodialysis.

Authors:  Tamara Isakova; Orlando M Gutiérrez; Yuchiao Chang; Anand Shah; Hector Tamez; Kelsey Smith; Ravi Thadhani; Myles Wolf
Journal:  J Am Soc Nephrol       Date:  2008-12-17       Impact factor: 10.121

8.  Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency.

Authors:  Takashi Shigematsu; Junichiro James Kazama; Takeyoshi Yamashita; Seiji Fukumoto; Tatsuo Hosoya; Fumitake Gejyo; Masafumi Fukagawa
Journal:  Am J Kidney Dis       Date:  2004-08       Impact factor: 8.860

9.  Relationship between circulating FGF23 and total body atherosclerosis in the community.

Authors:  Majd A I Mirza; Tomas Hansen; Lars Johansson; Håkan Ahlström; Anders Larsson; Lars Lind; Tobias E Larsson
Journal:  Nephrol Dial Transplant       Date:  2009-05-09       Impact factor: 5.992

10.  Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease.

Authors:  Orlando M Gutiérrez; James L Januzzi; Tamara Isakova; Karen Laliberte; Kelsey Smith; Gina Collerone; Ammar Sarwar; Udo Hoffmann; Erin Coglianese; Robert Christenson; Thomas J Wang; Christopher deFilippi; Myles Wolf
Journal:  Circulation       Date:  2009-05-04       Impact factor: 29.690

View more
  2 in total

Review 1.  Inflammation: a putative link between phosphate metabolism and cardiovascular disease.

Authors:  Jakob Voelkl; Daniela Egli-Spichtig; Ioana Alesutan; Carsten A Wagner
Journal:  Clin Sci (Lond)       Date:  2021-01-15       Impact factor: 6.124

Review 2.  Cardiotoxicity of Uremic Toxins: A Driver of Cardiorenal Syndrome.

Authors:  Suree Lekawanvijit
Journal:  Toxins (Basel)       Date:  2018-09-01       Impact factor: 4.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.